Thrombocytopenia associated with second-line carboplatin-based chemotherapy for ovarian, fallopian tube, and primary peritoneal cavity cancers

被引：0
|
作者：
Maurie Markman
Jon Markman
Kenneth Webster
Kristine Zanotti
Barbara Kulp
Gertrude Peterson
Jerome Belinson
机构：
[1] University of Texas M.D. Anderson Cancer Center ,Departments of Hematology/Medical Oncology and Gynecology/Obstetrics
[2] The Cleveland Clinic Foundation,undefined
来源：
Journal of Cancer Research and Clinical Oncology | 2004年 / 130卷
关键词：
Thrombocytopenia; Carboplatin; Ovarian cancer; Chemotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：741 / 744
页数：3
相关论文
共 50 条
  • [21] Deliverability of Carboplatin and Weekly Paclitaxel as Adjuvant Therapy for Ovarian, Fallopian Tube and Primary Peritoneal Cancer Patients
    Sivakumaran, T.
    Zaheed, M.
    Freimund, A.
    Beale, P.
    Harrison, M.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 72 - 72
  • [22] Recurrence patterns after extended treatment with bevacizumab for ovarian, fallopian tube, and primary peritoneal cancers
    Dao, Minh D.
    Alwan, Laura M.
    Gray, Heidi J.
    Tamimi, Hisham K.
    Goff, Barbara A.
    Liao, John B.
    GYNECOLOGIC ONCOLOGY, 2013, 130 (02) : 295 - 299
  • [23] Primary Chemotherapy for Inoperable Ovarian, Fallopian Tube, or Primary Peritoneal Cancer With or Without Delayed Debulking Surgery
    Saha, Antonio
    Varughese, Mohini
    Gallagher, Chris J.
    Orphanos, George
    Wilson, Peter
    Oram, David
    Jeyarajah, Arjun
    Reynolds, Karina
    Shepherd, John
    McCormack, Mary
    Olaitan, Adeola
    McDonald, Nicola
    Mould, Tim
    McNeish, Iain
    Ledermann, Jonathan A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2012, 22 (04) : 566 - 572
  • [24] A phase Ib trial of erlotinib (E) in combination with docetaxel (D) and carboplatin (C) in untreated ovarian, fallopian tube and primary peritoneal cancers.
    Vasey, P
    Kaye, S
    Paul, J
    Rustin, G
    Wilson, R
    Guastalla, JP
    Pujade-Lauraine, E
    Gore, M
    Gabra, H
    Carty, K
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 453S - 453S
  • [25] Eriotinib (E) in combination with docetaxel (D) and carboplatin (C): a phase Ib trial in patients with untreated ovarian, fallopian tube and primary peritoneal cancers
    Agarwal, R.
    Kaye, S.
    Vasey, P.
    Paul, J.
    Gore, M.
    Wilson, R.
    Rustin, G.
    Gabra, H.
    Guastalla, J. -P
    Carty, K.
    ANNALS OF ONCOLOGY, 2004, 15 : 127 - 127
  • [26] Efficacy of third-line chemotherapy for recurrent ovarian, peritoneal and fallopian tube carcinoma.
    Tremblay, A
    Harel, F
    Lavoie, A
    Leblanc, R
    Ouellet, P
    Tessier, C
    Lalancette, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 488S - 488S
  • [27] Patterns of recurrence in advanced epithelial ovarian, fallopian tube, and peritoneal cancers treated with intraperitoneal chemotherapy.
    Esselen, K. M.
    Rodriguez, N.
    Horowitz, N. S.
    Campos, S. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [28] Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer
    Nakabayashi, Mari
    Sartor, Oliver
    Jacobus, Susanna
    Regan, Meredith M.
    McKearn, David
    Ross, Robert W.
    Kantoff, Philip W.
    Taplin, Mary-Ellen
    Oh, William K.
    BJU INTERNATIONAL, 2008, 101 (03) : 308 - 312
  • [29] Subsequent chemotherapy is well tolerated in patients who underwent primary adjuvant intraperitoneal chemotherapy for ovarian, fallopian and primary peritoneal cancers
    Jewell, A.
    Fehniger, J.
    Stewart, C.
    Lengyel, E.
    Yamada, S. D.
    GYNECOLOGIC ONCOLOGY, 2015, 139 (01) : 203 - 203
  • [30] Third-line chemotherapy in platinum- and paclitaxel-resistant ovarian, fallopian tube, and primary peritoneal carcinoma patients
    Tangjitgamol, S
    See, HT
    Manusirivithaya, S
    Levenback, CF
    Gershenson, DM
    Kavanagh, JJ
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2004, 14 (05) : 804 - 814
12345